Liquid Biopsy Assay for early cancer detection
4D Lifetec AG
Incorporated
11.11.2014Headquarters
ChamSupport
4D Lifetec AG is the pioneering company in non-genomic, immuno-oncologic blood assays for early cancer diagnostic. Due to its proprietary transformational DDS biomarker, 4D Lifetest™ has several possibilities to expand its market activities, become a key element in the diagnostic cascade for other major cancer types and support genomic liquid biopsy methods by adding high early detection sensitivity (> 90% at Stage I). 4D Lifetest™ Lung Dx is the company’s flagship product which is marketed with an initial focus on early lung cancer diagnostic. Additional applications (4D Lifetest™ Breast Dx, 4D Lifetest™ Prostate Dx, 4D Lifetest™ Colon Dx) are already CE IVD certified and ready to access the markets.
4D Lifetec participated in the Venture Leaders Biotech program in 2019.
News
4D Lifetec secures CHF 23.3 million to enhance cancer diagnosis (startupticker.ch)
Empowering early cancer detection: 4D Lifetec secures CHF 23.3 million in a share and investment deal with Xlife Sciences (venturelab.swiss)
4D Lifetec establishes US presence with new branch office on MIT campus (venturelab.swiss)
4D LifeTec establishes a presence in the US market (startupticker.ch)
Seasoned executives to drive startups in the next phase (startupticker.ch)
Molecular Diagnostics to industrialise 4D Lifetest (startupticker.ch)
4D Lifetec banks CHF 1.9 in series B round (startupticker.ch)
Sino-Swiss Pitchinar: Selected Swiss biotech startups pitch to Chinese investors and enterprises (venturelab.swiss)
CE Certification for 4D Lifetec's cancer diagnostic platform (startupticker.ch)
4D Lifetec AG with first customers and R&D partner (startupticker.ch)
Venture Leaders 2019 Teams Celebrated at the US Embassy in Switzerland (venturelab.swiss)
A few lessons and thoughts from the Venture Leaders Life Sciences roadshow in Boston, 9-15 June 2019 by Danuta Cichocka (venturelab.swiss)
Milestones news
4D Lifetest™ Lung Dx receives CE-IVD mark
4D Lifetec files new patent for its transformational cancer biomarker DNA Damage Sensitivity (DDS)
Cooperation with the University Hospital Basel on lung cancer
Closing of Bridge Financing Series C
Cooperation with University Hospital St. Gallen on prostate cancer
Start cooperation with SAKK for the clinical study
Successfull set up of our own diagnostic lab facilities
Ready to use products 4D Lifetest™ for research only
Proof of concept of 4D Lifetest™ in co-operation with international cancer centres and first clinical investigations
Successful closing of Capital Round Series B
Successful finalisation of protoyping phase
Non-dilutive funding by CTI Switzerland
Verification study in co-operation with EMPA and establishing standardization protocol
Functional models and standardisation of the 4D Method
Initial funding of the startup in a Series A
Documents
